SEC EDGAROCT 21 min read$OBIO

Sherman Darren sold $95K of OBIO

Sherman Darren (See Remarks) sold 15,000 shares of Orchestra BioMed Holdings, Inc. (OBIO) at $6.36 on 2026-10-01 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Sherman Darren

Published Oct 2, 2026, 8:30 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 2, 2026, 8:38 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$OBIO

Neutral

medium confidence

Mentioned

$OBIO

Relevance

2/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$OBIONeutralLow

Why it matters

The transaction is modest in size and unlikely to move the stock significantly, but it adds transparency for investors monitoring insider activity.

Market read

A routine insider sale with limited market impact; useful for compliance monitoring but low trading relevance.

What to watch

Insider holds >1M shares post‑sale, indicating continued confidence.

Relevance 2/10Novelty 2/10Timing: after‑hours filing today

Background

SEC Form 4 filing provides the first public disclosure of the insider's share sale.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$OBIONeutralMedium confidence

Context

Form 4 disclosed Officer/Director Sherman Darren sold 15,000 shares at $6.36, reducing his stake to 1,119,402 shares.

Expected impact

likely slight pressure as the market prices in the insider sell

Evidence & confidence

Sale size (~$95k) is modest for a micro‑cap; no broader catalyst, so impact is limited.

Market effects

Sector

Minimal; biotech sector not affected by a single small insider transaction.

Regional

None

Global

None

Counterpoint

What could challenge this read

The sale could be routine liquidity need, not a negative signal.

Key entities

Company
Orchestra BioMed Holdings, Inc.
Biotech firm listed on NASDAQ under ticker OBIO.
Insider
Sherman Darren
Officer and Director of Orchestra BioMed Holdings.

Read at source ← All news

OCT 5

$OBIOMed

H.C. Wainwright reiterates Orchestra BioMed stock rating on trial enrollment

H.C. Wainwright reiterated a Buy rating and $10.00 price target for Orchestra BioMed (OBIO) after its hypertension trial completed enrollment. The stock trades at $5.95, with a 119.56% return over the past year. The BACKBEAT trial, conducted with Medtronic, aims to treat uncontrolled hypertension in pacemaker patients. Orchestra plans to submit results for regulatory review in 2027. BTIG also upgraded OBIO to Buy with a $10 target.

investing.com2 min

OCT 3

$OBIOMed

Analysts Offer Insights on Healthcare Companies: Orchestra BioMed Holdings (OBIO) and Regeneron (REGN)

Analysts from B. Riley Securities and TD Cowen reiterated Buy ratings on Orchestra BioMed Holdings (OBIO), with price targets of $11.00 and $15.00, respectively. Regeneron (REGN) received a Buy rating from Goldman Sachs with a $972.00 price target. Both stocks have bullish analyst consensus.

theglobeandmail.com2 min

OCT 2

$KODMed

Biotech Stocks At 52-Week Highs - KOD, MASS, OBIO, CDNA, PMVP

Kodiak Sciences (KOD) rose 3% to $104 after positive Phase 3 trial results. 908 Devices (MASS) hit $12.93 with Q2 revenue up 23%. Orchestra BioMed (OBIO) reached $6.20, expanding Q2 loss by 23%. CareDx (CDNA) hit a 52-week high with Q2 revenue up 52%. PMV Pharmaceuticals (PMVP) rose 4% to $1.91 on positive clinical data.

rttnews.com2 min

OCT 1

$OBIOMedAI 8/10

Orchestra Bio exceeds BACKBEAT trial enrollment with 330 randomized patients

Orchestra BioMed (OBIO) completed its BACKBEAT trial with 330 patients, exceeding the 316-patient target. The global trial, conducted at 81 sites across 13 countries, aims to support Medtronic's regulatory applications. Primary endpoint data is expected to be submitted for presentation in Q2 2027, according to the company.

tradingview.com1 min

OCT 1

$OBIOLow

Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy

Orchestra BioMed Holdings, Inc. (OBIO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy · 330 patients randomized as of September 30, 2026, surpassing full trial enrollment target · Company reiterates prior guidance: primary endpoint data to be submitted

SEC EDGAR 8-K2 min

AUG 19

$AMLXHighAI 8/10

Biotech Stocks At 52-Week Highs - AMLX +63% With Phase 3 Data, VOGX +25%, OBIO +19%, ATRC, CRL

Several biotech stocks hit 52-week highs on August 18, 2026. Amylyx (AMLX) surged 63% to $35.39 after positive Phase 3 data and a $350M share offering. Vogenx (VOGX) rose 25% to $20.01 post-IPO. AtriCure (ATRC) reached $46.33 with 12.8% revenue growth. Charles River (CRL) hit $289.60 despite a 2.7% revenue dip. Orchestra BioMed (OBIO) climbed 19% to $5.77 with FDA breakthrough designations.

rttnews.com3 min